Psorion Psoriasis Cream

Additional Information

Psoriasis is a chronic inflammatory disease that is estimated to affect 2-3% of the Indian population. Psoriasis is characterized by hyperproliferation of keratinocytes and dermal infiltration by activated T cells, neutrophils, and dendritic cells. There are seven types of psoriasis namely Plaque psoriasis, Guttate psoriasis, Inverse/flexual psoriasis, Pustular psoriasis, Erythrodermic psoriasis, Nail psoriasis and Psoriatic arthritis. The symptoms include irritation, dryness, redness, flaky patches of skin, genital sores, pain in joints, thickening & browning of nails and severe dandruff.

Psoriasis is characterized by hyperproliferation of keratinocytes and dermal infiltration by activated T cells, neutrophils, and dendritic cells. Psoriasis involves keratinocytes, antigen-presenting cells, neutrophilic granulocytes, vascular endothelial cells, and the cutaneous nervous system. The infiltrated psoriatic lesions have significantly increased levels of the CD4 T-cell subsets T helper (Th1 and Th17). The contribution of distorted immune activation has been proved to target some key immune components, namely IL-23, tumor necrosis factor alpha, and the Th17/IL-23 axis. The infiltrated psoriatic lesions have significantly increased levels of the CD4 T-cell subsets T helper (Th)1 and Th17. The immune genes are responsible for several functions that involve innate immunity, antigen presentation, the interleukin (IL)-23 axis, and T-cell development and polarization. In recent years, the contribution of some of these gene products to psoriasis has been proved to target some key immune components, namely IL-23, tumor necrosis factor alpha (TNF-α), and the Th17/IL-23 axis. TNF-α is a pro-inflammatory cytokine, produced by different cell types including lymphocytes, keratinocytes, endothelial cells, and macrophages, which amplifies inflammation response through several pathways. The IL-23/Th17 axis could be a novel targeted therapy for the treatment of psoriasis. Th17 cells are a subset of T-lymphocytes that express IL17, different from the classical Th17 cells, that have a significant role in the pathogenesis of inflammatory disorders including psoriasis.

Due to the side effects and safety concerns of the long-term use of therapies, treatment selection is challenging. An increasing number of psoriatic patients are seeking alternative therapies.
Patients with moderate psoriasis identified IL-17 as a key pathway that can be modulated by treatment with Indigo naturalis. Clinical studies have demonstrated that Indigo naturalis used as topical monotherapy is efficacious in treating patients with mild-to-moderate psoriasis, although the validity of these studies is challenged by intra-patient treatment comparison designs. One component of Indigo naturalis, indirubin, was reported to inhibit cyclin-dependent kinase and signal transducer and activator of transcription-3 (STAT3) activities, and keratinocyte proliferation. Moreover, Indigo naturalis extract has been shown to inhibit oxygen generation and elastase release in formyl-methionyl-leucylphenylalanine- induced human neutrophils in vitro. Indigo naturalis significantly down-regulated the IL-17 pathway in affected skin, similar to other therapies that successfully target this pathway. Moreover, we showed that one of the chemical components in Indigo naturalis, tryptanthrin, possesses moderate anti-IL-17 activity.

Curcumin is a polyphenol derived from the golden spice turmeric (“Curcuma longa”). Because of its numerous properties (e.g. anti – oxidant, anti -proliferative, anti-inflammatory), curcumin has been used for the treatment of psoriasis. The anti-inflammatory properties of curcumin have been showed in the serum as a decrease of more than 50% in the level of inflammatory factors, including TNF – α, IFN – γ, IL – 2, IL – 12, IL – 22 and IL – 23.